Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches.
Drug Discov Today Technol
; 39: 1-12, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1284030
ABSTRACT
Standing amidst the COVID-19 pandemic, we have faced major medical and economic crisis in recent times which remains to be an unresolved issue till date. Although the scientific community has made significant progress towards diagnosis and understanding the disease; however, effective therapeutics are still lacking. Several omics-based studies, especially proteomics and interactomics, have contributed significantly in terms of identifying biomarker panels that can potentially be used for the disease prognosis. This has also paved the way to identify the targets for drug repurposing as a therapeutic alternative. US Food and Drug Administration (FDA) has set in motion more than 500 drug development programs on an emergency basis, most of them are focusing on repurposed drugs. Remdesivir is one such success of a robust and quick drug repurposing approach. The advancements in omics-based technologies has allowed to explore altered host proteins, which were earlier restricted to only SARS-CoV-2 protein signatures. In this article, we have reviewed major contributions of proteomics and interactomics techniques towards identifying therapeutic targets for COVID-19. Furthermore, in-silico molecular docking approaches to streamline potential drug candidates are also discussed.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Repositioning
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Drug Discov Today Technol
Year:
2021
Document Type:
Article
Affiliation country:
J.ddtec.2021.06.004
Similar
MEDLINE
...
LILACS
LIS